Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer

 

Siamak Daneshmand M.D., Ashish M. Kamat M.D., M.B., B.S., Neal D. Shore M.D., Joshua J. Meeks M.D., Ph.D., Matthew D. Galsky M.D., Joseph M. Jacob M.D., Michiel S. van der Heijden M.D., Ph.D., Stephen B. Williams M.D., M.B.A., M.S., Thomas Powles M.D., Sam S. Chang M.D., James W.F. Catto Ph.D., F.R.C.S. (Urol.), Sarah P. Psutka M.D., Félix Guerrero-Ramos M.D., Ph.D., Evanguelos Xylinas M.D., Makito Miyake M.D., Ph.D., Giuseppe Simone M.D., Ph.D., Karen Daniel Ph.D., Hussein Sweiti M.D., Christopher Cutie M.D., Andrea Necchi M.D.

Click here to read entire article

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Neal D. Shore, MD, Lead Investigator for the CREST trial.

Click here to read entire article

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

Authors: Neal Shore, MD , Sarah M. Nielsen, MS , Edward D. Esplin, MD, PhD, Emmanuel S. Antonarakis, MD, Pedro C. Barata, MD, Tomasz M. Beer, MD, Himisha Beltran, MD, Alan Bryce, MD, Michael S. Cookson, MD, E. David Crawford, MD, Tanya B. Dorff, MD, Daniel J. George, MD, Elisabeth I. Heath, MD, Brian T. Helfand, MD, PhD, Maha Hussain, MD, Rana R. Mckay, MD, Alicia K. Morgans, MD, MPH, Michael J. Morris, MD, Channing J. Paller, MD, Ashley E. Ross, MD, PhD, Oliver Sartor, MD, John Shen, MD, Paul Sieber, MD, Matthew R. Smith, MD, PhD, David R. Wise, MD, PhD, Andrew J. Armstrong, MD 

Click here to read entire article

In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?

Authors:

Jason R. Brown, MD, PhD (University Hospitals Seidman Cancer Center, Cleveland, Ohio / Case Comprehensive Cancer Center, Cleveland, Ohio)
Neal Shore, MD (Carolina Urologic Research Center, Myrtle Beach, South Carolina)
Pedro C. Barata, MD, MSc (University Hospitals Seidman Cancer Center, Cleveland, Ohio / Case Comprehensive Cancer Center, Cleveland, Ohio)
 

Click here to read entire article

Editorial Comment: Integrating Broad Panel Somatic and Germline Testing in Prostate Cancer Care

Author Neal Shore, MD, FACS, Carolina Urologic Research Center, AUC Urology Specialists, 823 82nd Parkway, Myrtle Beach, SC , 29572

Click here to read entire article

Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology

Authors: Neal Shore ∙ Gordon Brown ∙ Benjamin Lowentritt ∙ Lorraine O’Donnell ∙ Wanda Wilt ∙ Sabree Burbage ∙ Ibrahim Khilfeh  ∙ Franklin Gaylis

Click here to read entire article

Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer

Neal D Shore* , Alicia K Morgansb and Ronald F Tutrone

Click here to read entire article

Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK

Authors Neal D. Shore, Ugo De Giorgi, and Stephen J. Freedland

Click here to read entire article

Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer

 

Authors: Neal Shore1. Joan Carles2. Ray McDermott3.  Neeraj Agarwal4. Bertrand Tombal5*